Search

A 74-year-old woman with central nervous system-relapsed mantle cell lymphoma experienced grade 1 cytokine release syndrome and grade 2 immune effector cell-associated neurotoxicity syndrome during treatment with brexucabtagene-autoleucel. She also showed a lack of efficacy with various other treatments, including rituximab, ibrutinib, methotrexate, cytarabine, dexamethasone, and tocilizumab. Despite these challenges, the woman achieved complete remission of mantle cell lymphoma after treatment with brexucabtagene-autoleucel. [Extracted from the article]

A man with refractory stage IVB mantle cell lymphoma exhibited lack of efficacy during treatment with rituximab and ibrutinib. Despite previous treatments and autologous stem cell transplant, his lymphoma continued to progress. He underwent CAR-T-cell therapies, which resulted in complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Post-treatment, he developed sclerosing cholangitis and his condition worsened, leading to a transition to comfort care. [Extracted from the article]

A man with refractory stage IVB mantle cell lymphoma exhibited lack of efficacy during treatment with rituximab and ibrutinib. Despite previous treatments and autologous stem cell transplant, his lymphoma continued to progress. He underwent CAR-T-cell therapies, which resulted in complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Post-treatment, he developed sclerosing cholangitis and his condition worsened, leading to a transition to comfort care. [Extracted from the article]

This article discusses two case reports of women with chronic lymphocytic leukemia (CLL) and Richter syndrome (RS) who experienced cytokine release syndrome and lack of efficacy during treatment with various antineoplastic drugs. The first patient received RCHOP regimen, brentuximab-vedotin, and CAR-T cell therapy, while the second patient received ibrutinib, venetoclax, obinutuzumab, RCHOP regimen, and CAR-T cell therapy. Both patients experienced cytokine release syndrome and were treated with tocilizumab. The first patient achieved complete remission, while the second patient achieved partial response and underwent stem cell transplantation. [Extracted from the article]

A 39-year-old man experienced grade 2 mucositis and grade 2 cytokine release syndrome (CRS) while being treated for diffuse large B-cell lymphoma with relmacabtagene-autoleucel. He also had a lack of efficacy with various other treatments for follicular lymphoma and diffuse large B-cell lymphoma. Despite these complications, he eventually achieved complete metabolic remission after receiving relmacabtagene-autoleucel and maintenance therapy with ibrutinib. [Extracted from the article]

A 45-year-old woman experienced myelodysplasia, trilinear cytopenia, and cytokine release syndrome while being treated with tisagenlecleucel for relapsed/refractory diffuse large B cells lymphoma. She also showed lack of efficacy during treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, bendamustine, methotrexate, and erythropoietin for low-grade lymphoma or anemia. The woman underwent autologous stem cell transplantation and received CAR-T therapy with tisagenlecleucel infusion. She experienced complications such as cytokine release syndrome and grade 4 trilinear cytopenia, but eventually achieved complete remission of the lymphoma. However, she developed myelodysplasia secondary to tisagenlecleucel and experienced persistent cytopenia, although it improved over time. [Extracted from the article]

A 49-year-old man with primary central nervous system lymphoma (PCNSL) exhibited lack of efficacy during treatment with rituximab, methotrexate, and cytarabine. After starting treatment with rituximab and methotrexate, new lesions were found on a cranial MRI, indicating disease progression. The treatment was then switched to cytarabine, but after 13 days, a cranial CT showed further lack of efficacy. The patient was subsequently treated with lenalidomide, ibrutinib, whole-brain radiation therapy, camrelizumab, CAR-T therapy, decitabine, cyclophosphamide, and fludarabine. He developed cytokine releasing syndrome but eventually achieved complete remission and is currently receiving maintenance therapy. [Extracted from the article]

A retrospective analysis of 25 patients with large B-cell lymphoma (LBCL) found that one patient developed cytokine release syndrome (CRS) during treatment with polatuzumab-vedotin, bendamustine, and rituximab. The patient underwent leukapheresis and received bridging chemotherapy with the aforementioned drugs. However, they experienced grade 3 or worse CRS as a result of the treatment. The specific details regarding dosages, routes, durations of treatments, and the patient's outcome were not provided. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 68-year-old man developed cytokine release syndrome (CRS) during treatment with rituximab for B-cell lymphoma [route, dosage and duration of treatment to reaction onset not stated]. [Extracted from the article]

This article presents a case series of six patients, five men and one woman aged 50-60 years, who experienced various toxicities and lack of efficacy during treatment for lymphoma. The patients received different therapies, including tisagenlecleucel, lisocabtagene-maraleucel, axicabtagene-ciloleucel, rituximab, oxaliplatin, gemcitabine, cyclophosphamide, doxorubicin, vincristine, prednisone, ifosfamide, etoposide, and methotrexate. The toxicities observed included tumour pseudoprogression, cytokine release syndrome, and immune effector cell-associated neurotoxicity syndrome. Some patients achieved complete remission with certain therapies, while others experienced progressive disease. [Extracted from the article]

This article describes four case reports of patients who experienced various toxicities and no therapeutic response while being treated with tisagenlecleucel for diffuse large B-cell lymphoma (DLBCL). The patients developed cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or pancytopenia during treatment. Despite receiving other treatments such as rituximab, dexamethasone, cisplatin, cytarabine, gemcitabine, or etoposide, they did not show a therapeutic response. The article provides details about each patient's medical history, treatment, and outcomes. [Extracted from the article]

Chemotherapy regimen was then adjusted to bendamustine plus VTD regimen comprising bortezomib, thalidomide and dexamethasone. Patient 1: The 65-year-old woman was admitted with a diagnosis of R/R MM. Chemotherapy was initiated with 2 cycles of the PAD regimen comprising bortezomib, doxorubicin [Adriamycin] and dexamethasone. Multiple chemotherapies were initiated following diagnosis, including the R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, and R-DICE regimen comprising rituximab, dexamethasone, ifosfamide, cisplatin and etoposide, and P-GEMOX regimen comprising pegaspargase, oxaliplatin and gemcitabine. [Extracted from the article]

He received six courses of an R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, and two additional doses of rituximab. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 56-year-old man exhibited lack of efficacy during treatment with rituximab, gemcitabine, oxaliplatin, cyclophosphamide and prednisone for post-transplant lymphoproliferative disorder (PTLD). He was prescribed bridging therapy with 2 cycles of cyclophosphamide 500 mg/m SP 2 sp day 1 and prednisone 60 mg/m SP 2 sp day 1-5. [Extracted from the article]

Therefore, she started receiving salvage therapy R-ESHAP regimen comprising rituximab, doxorubicin, etoposide, cytarabine [aracytine] and prednisolone was commenced. Subsequently, she developed immune effector-cell neurotoxicity syndrome and grade 4 cytokine release syndrome secondary to axicabtagene-ciloleucel. Subsequently, she developed cytokine release syndrome and immune effector-cell neurotoxicity syndrome during treatment with axicabtagene-ciloleucel, and pneumonitis during off label treatment with pembrolizumab for PMLBCL [ I routes and dosages not stated i ]. [Extracted from the article]

He had also been receiving immunosuppressive therapy for kidney transplant consisting of mycophenolate mofetil, which was discontinued at the time of DLBCL diagnosis, tacrolimus was discontinued 2 weeks prior the leukapheresis, and prednisone was continued. Further, they developed cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment with axicabtagene-ciloleucel for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). [Extracted from the article]

However, the treatment course was remarkable for early onset (within 72h of CAR-T infusion) fevers consistent with grade 1 cytokine release syndrome (CRS) by ASTCT consensus criteria. Her post-treatment course was complicated by a multidrug-resistant I Escherichia coli i (E. coli) urinary tract infection (UTI), requiring hospital admission for antibiotic treatment. [Extracted from the article]

Case 4: A patient [ I age and sex not stated i ] developed I Escherichia coli i infection following lymphodepletion chemotherapy with fludarabine, cyclophosphamide and unspecified CAR-T-cell therapy for relapsed/refractory lymphoma. Case 5: A patient [ I age and sex not stated i ] developed bronchoalveolar I Aspergillus fumigatus i infection following lymphodepletion chemotherapy with fludarabine, cyclophosphamide and unspecified CAR-T-cell therapy for relapsed/refractory lymphoma. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective cohort study of 60 patients treated between September 2018 and September 2020, six patients including two men and one woman aged 68-72 years [ I not all ages and sexes stated i ] were described, who developed neurotoxicity, cytomegalovirus (CMV) reactivation pneumonia, acute kidney failure, respiratory syncytial virus (RSV) pneumonia, cytomegalovirus infection, cytokine release syndrome, I Escherichia coli i infection, bronchoalveolar I Aspergillus fumigatus i infection or parainfluenza virus infection following treatment with fludarabine, cyclophosphamide, axicabtagene-ciloleucel, unspecified CAR-T-cell therapy or foscarnet [ I dosages and routes not stated i ; I not all durations of treatments to reactions onsets and outcomes stated i ]. [Extracted from the article]

Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 15-year-old boy exhibited treatment failure during treatment with daunorubicin, pegaspargase, prednisone and vincristine for pre-B acute lymphoblastic leukaemia. Subsequently, he developed cytokine release storm following treatment with tisagenlecleucel for relapse of pre-B acute lymphoblastic leukaemia [ I routes and dosages not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An adult woman [ I age at the time of reaction onset not stated i ] developed cytokine release syndrome and multifocal necrotising leukoencephalopathy with preferential microglia toxicity following administration of fludarabine, cyclophosphamide, vincristine, doxorubicin, dexamethasone, etoposide, prednisone, methotrexate, cytarabine, inotuzumab-ozogamicin and axicabtagene ciloleucel for diffuse large B-cell lymphoma [ I dosages not stated; not all routes stated i ]. Thereafter, she experienced her first relapse and started receiving salvage therapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH). [Extracted from the article]

The percentage of CAR-T cells in the CD3+T cells was 73.5%, whereas CAR-T cell percentages in the peripheral blood and skin biopsy specimen were found 67.2% and 19.6%, respectively. Reference 1 Hu Y. Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A man in his 40s [ I exact age not stated i ] developed bullous and exanthematous lesions and grade 3 cytokine release syndrome during treatment with AUTO-3 for relapsed/refractory B-cell lymphoma. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series consisting of four patients, a 13-year-old girl (patient 1) [1] developed cytokine release syndrome following treatment with rituximab for large B-cell lymphoma. Cytokine release syndrome was considered as possible cause of her deterioration and death. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 66-year-old woman developed cardiomyopathy following treatment with doxorubicin for diffuse large B-cell lymphoma (DLBCL) and cytokine release syndrome (CRS) during treatment with axicabtagene ciloleucel for DLBCL [ I dosages and routes not stated i ]. The woman, who was diagnosed with advanced DLBCL 6 years prior, was referred for chimeric antigen receptor T-cell (CART) therapy. After reviewing the clinical findings, cardio-oncologist suggested CART therapy as the best therapeutic option. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 31-year-old man developed grade 1 cytokine release syndrome following administration of anti-CD19-CAR-transduced-T-cells and he developed grade 3 cytokine release syndrome and hemophagocytic syndrome following an administration of auto-3 for diffuse large B-cell lymphoma (DLBCL). Within 12 h following the infusion, he developed grade 1 cytokine release syndrome with fever. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An 18-year-old girl developed cytokine release syndrome and immune effector cell associated neurotoxicity syndrome during treatment with axicabtagene ciloleucel, cyclophosphamide, methylprednisolone, rituximab and fludarabine for primary mediastinal large B-cell lymphoma (PMLBCL) [ I routes not stated; not all dosages stated i ]. On day +4, she developed cytokine release syndrome (grade 1) and on day+5, she developed immune effector cell-associated neurotoxicity syndrome (grade 3) secondary to axicabtagene ciloleucel, methylprednisolone, fludarabine, rituximab and cyclophosphamide. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 68-year-old woman developed cytokine release syndrome, neurotoxicity, prolonged neutropenia, hypogammaglobulinaemia, lymphopenia, reactivation of the JC virus (JCV) and progressive multifocal leukoencephalopathy (PML) during treatment with axicabtagene ciloleucel for recurrent diffuse large B-cell lymphoma. One month later, a PET/CT showed complete metabolic remission and there was no evidence of disease relapse. A repeat PET/CT showed a continuous remission in the diffuse large B-cell lymphoma. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 57-year-old man developed cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cardiac toxicities and dysautonomia during treatment with axicabtagene-ciloleucel for diffuse large B-cell lymphoma. A CSF test was found to be negative for lymphoma; however, the CSF test was found to be positive for type B human herpes virus 6 (HHV6). Severe dysautonomia as a manifestation of neurotoxicity after CAR-T cell therapy for diffuse large B-cell lymphoma. [Extracted from the article]